Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Slides:

Advertisements

Similar presentations

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Advertisements

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Dyslipidemia and Diabetic Macular Edema

Wijtske Annema, PhD, Hendrik M

Copyright © 2011 American Medical Association. All rights reserved.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Aspirin Use Among U.S. Adults

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Liver Safety Task Force: 2014 update

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Rounding numbers The Journal of Thoracic and Cardiovascular Surgery

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men Gloria Lena Vega, PhD, Scott M. Grundy,

The Burden of Modifiable Risk Factors in Newly Defined Categories of Blood Pressure Anna Gu, MD, PhD, Yu Yue, PhD, Joohae Kim, PharmD Candidate, Edgar.

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study Tim Christen, MSc, Stella.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Meredith Kilgore, PhD, Paul Muntner, PhD, J

Non–high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf

Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? Joana Rita Chora, MSc, Ana Catarina Alves, PhD, Ana.

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial James D. Otvos,

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018 Liam R. Brunham, MD, PhD, Isabelle Ruel, PhD, Sumayah.

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.

Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles Jan.

Simplified Canadian Definition for Familial Hypercholesterolemia

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum Martin Czerny, MD, MBA The Journal.

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Xing Wu, MD, PhD, Zhexin Yu, MD, MS, Wen Su, MD, PhD, Daniel A

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Optimal high-density lipoprotein cholesterol cutoff for predicting cardiovascular disease: Comparison of the Korean and US National Health and Nutrition.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical.

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Volume 67, Issue 4, Pages (April 2005)

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia Merel L. Hartgers, MD, Joep.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results.

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

Urbanization, mainly rurality, but not altitude is associated with dyslipidemia profiles Maria Lazo-Porras, Antonio Bernabe-Ortiz, Renato Quispe, German.

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design Dirk J. Blom, MD, PhD, Zahi A. Fayad,

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

Presentation transcript:

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie Bernard, MD, PhD, Isabelle Ruel, PhD, David W. Blank, MD, Jacques Genest, MD, Alexis Baass, MD, MSc Journal of Clinical Lipidology Volume 13, Issue 1, Pages 123-128 (January 2019) DOI: 10.1016/j.jacl.2018.09.008 Copyright © 2018 National Lipid Association Terms and Conditions

Figure 1 Flowchart of study. CVD, cardiovascular disease; DLCN, Dutch lipid clinic network; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; HTN, hypertension. Journal of Clinical Lipidology 2019 13, 123-128DOI: (10.1016/j.jacl.2018.09.008) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 2 Average value of the Montreal-FH-SCORE in diabetic compared to nondiabetic FH patients. FH, familial hypercholesterolemia. Journal of Clinical Lipidology 2019 13, 123-128DOI: (10.1016/j.jacl.2018.09.008) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 3 Prevalence of CVD in diabetic compared to nondiabetic FH patients. CI, confidence interval; CVD, cardiovascular disease; FH, familial hypercholesterolemia; OR, odds ratio. Journal of Clinical Lipidology 2019 13, 123-128DOI: (10.1016/j.jacl.2018.09.008) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 4 Average number of CVD events per individual in the diabetic group compared to the nondiabetic group. CVD, cardiovascular disease. N = 668. Journal of Clinical Lipidology 2019 13, 123-128DOI: (10.1016/j.jacl.2018.09.008) Copyright © 2018 National Lipid Association Terms and Conditions